shizukaol D: isolated from Chloranthusjaponicus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 70698151 |
| CHEMBL ID | 3810102 |
| CHEBI ID | 69785 |
| MeSH ID | M0592477 |
| Synonym |
|---|
| shizukaol d |
| CHEBI:69785 |
| 142279-42-3 |
| CHEMBL3810102 |
| Q27138127 |
| methyl (2z)-2-[(1r,2s,8s,9r,10s,12r,13s,14s,17s,19r,20s,21r)-9-(acetyloxymethyl)-21-hydroxy-5-(hydroxymethyl)-13,20-dimethyl-4,22-dioxo-3-oxaoctacyclo[14.7.1.02,6.02,14.08,13.010,12.017,19.020,24]tetracosa-5,16(24)-dien-23-ylidene]propanoate |
| AKOS040762343 |
| FS-10343 |
| HY-N1302 |
| CS-0016706 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| triterpenoid | Any terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1537348 | Cytotoxicity against mouse RAW264.7 cells assessed as cellular metabolic activity at 50 uM after 48 hrs by MTT assay relative to control | 2019 | Journal of natural products, 02-22, Volume: 82, Issue:2 | Chloraserrtone A, a Sesquiterpenoid Dimer from Chloranthus serratus. |
| AID1537347 | Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess reagent based colorimetric method | 2019 | Journal of natural products, 02-22, Volume: 82, Issue:2 | Chloraserrtone A, a Sesquiterpenoid Dimer from Chloranthus serratus. |
| AID1303557 | Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay | 2016 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13 | Natural nitric oxide (NO) inhibitors from Chloranthus japonicus. |
| AID1437493 | Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 assessed as parasite growth inhibition after 72 hrs by SYBR Green 1 assay | 2017 | Journal of natural products, 01-27, Volume: 80, Issue:1 | Nanomolar Antimalarial Agents against Chloroquine-Resistant Plasmodium falciparum from Medicinal Plants and Their Structure-Activity Relationships. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.48) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||